GlassScriptPhysician profile
Liza M Brown
NPI 1487064580
$28,929.32
in general payments reported to CMS, 2019-2025
32 companies · $15K in 2025
The $15K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $362 · 2021: $1,218 · 2022: $1,368 · 2023: $2,025 · 2024: $8,160 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $7,983 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,118.00 |
| Food and Beverage | $7,982.62 |
| Education | $270.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $19,735.50 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Abbvie INC. | $1,537.51 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Regeneron Healthcare Solutions, INC. | $953.61 | 2020-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $713.89 | 2019-2025 | |
| Ucb, INC. | $693.30 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $635.61 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $618.60 | 2019-2025 | |
| Leo Pharma INC. | $571.37 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $502.79 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $468.10 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $353.63 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $329.16 | 2019-2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $319.84 | 2020-2025 | Blu-U, Ilumya, Odomzo |
| Incyte Corporation | $207.77 | 2021-2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.04 | 2022-2025 | Spevigo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $159.86 | 2022-2025 | Otezla, Otezla |
| Organogenesis INC. | $156.23 | 2024-2025 | Via Matrix, Cygnus Dual, Novachor |
| Prugen, INC. Pharmaceuticals | $134.48 | 2019 | |
| Biofrontera INC. | $105.45 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $79.42 | 2019-2023 | Seysara |
| Arcutis Biotherapeutics, INC. | $75.76 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $73.22 | 2022-2023 | Jublia |
| Journey Medical Corporation | $57.17 | 2023 | |
| Allergan, INC. | $48.45 | 2020-2021 | |
| Hill Dermaceuticals, INC. | $42.00 | 2023 | Tolak |
| Dermavant Sciences, INC. | $40.58 | 2023 | Vtama |
| Botanix Sb INC | $37.22 | 2025 | Sofdra |
| Dusa Pharmaceuticals, INC. | $22.17 | 2019 | |
| Vyne Pharmaceuticals INC. | $21.93 | 2020 | |
| Verrica Pharmaceuticals INC. | $20.31 | 2023 | Ycanth |
| Celgene Corporation | $18.35 | 2019 | |
| Organon LLC | $6.00 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liza Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.